1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsResearch Grants in Cognitive Neuroscience is sponsored by National Institute of Neurological Disorders and Stroke (NINDS). Research Grants in Cognitive Neuroscience is a grant from the National Institute of Neurological Disorders and Stroke (NINDS) that funds investigator-initiated research advancing scientific understanding of cognitive processes and their neural bases.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
[](https://www. ninds. nih.
gov/funding/find-funding-opportunities/notices) Notice of Change: NINDS Participation in "Mentored Research Scientist Development Award (Parent K01) Expiration Date: Monday, January 1, 2029 NOFO Number: NOT-NS-26-001 pThe purpose of this Notice is to inform potential applicants that the National Institute of Neurological Disorders and Stroke (a href="https://www. ninds. nih.
gov/"NINDS/a) is participating, effective for the February/March 2026 receipt dates, in the following Mentored Research Scientist Development Award (Parent K01) Notices of Funding Opportunity:/pulli/li/ul Native Collective Research Effort to Enhance Wellness (N CREW) Program: Addressing Overdose, Substance Use, Mental Health, and Pain Native Research Resource Partners Expiration Date: Monday, January 1, 2029 NOFO Number: NOT-DA-26-011 pNotice of publication of a ROA/p Native Collective Research Effort to Enhance Wellness (N CREW) Program: Addressing Overdose, Substance Use, Mental Health, and Pain Advancing Native Research Projects Expiration Date: Monday, January 1, 2029 NOFO Number: NOT-DA-26-012 pNotice of publication of a ROA/p Expiration Date: Monday, January 1, 2029 NOFO Number: NOT-NS-26-038 Notice of NINDS's Participation in PA-25-304: NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed) Expiration Date: Monday, January 1, 2029 NOFO Number: NOT-NS-26-009 pThe purpose of this Notice is to inform potential applicants of NINDS's participation in a href="https://grants.
nih. gov/grants/guide/pa-files/PA-25-304. html"PA-25-304/a: NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed), effective for the June 16, 2026, due date and subsequent due dates.
/ppThe following changes and updates (shown inistrong bold italics/strong/i) are made to a href="https://grants. nih. gov/grants/guide/pa-files/PA-25-304.
html"PA-25-304/a to reflect NINDS's participation in this notice of funding opportunity announcement (NOFO). /ppstrongAssistance Listing Number(s)/strong: 93. 865, 93.
173, 93. 867, 93. 879, 93.
121, 93. 286, 93. 273, 93.
855, 93. 242, 93. 172, 93.
279, 93. 361, 93. 866, 93.
113, 93. 143, 93. 213, 93.
310, 93. 307, 93. 846, istrong93.
853/strong/i, 93. 393, 93. 394, 93.
395, 93. 396, 93.
399/p Notice of Change: NINDS Expiration of PA-25-150: Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21) Clinical Trial Not Allowed) Expiration Date: Monday, January 1, 2029 NOFO Number: NOT-NS-26-007 Notice of Change: Early Expiration of PAR-25-326 Ultra-Rare Gene-based Therapy (URGenT) Network Resource Access (X01, Clinical Trial Not Allowed) Expiration Date: Monday, January 1, 2029 NOFO Number: NOT-NS-26-032 pThe purpose of this notice is to inform the extramural community that, effective immediately, the following NOFO is expired:/ppa href="https://grants.
nih. gov/grants/guide/pa-files/PAR-25-326. html"PAR-25-326/a: Ultra-Rare Gene-based Therapy (URGenT) Network Resource Access (X01, Clinical Trial Not Allowed)/pp/ppApplicants interested in applying to the Ultra-rare Gene-based Therapy (URGenT) programare encouraged to continue applying to the following NOFO:/ppa href="https://grants.
nih. gov/grants/guide/pa-files/PAR-25-327.
html"PAR-25-327/a: Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)/pp/p Notice to Rescind NOT-NS-24-060 "NINDS' Policy on Special Council Review of Research Applications" Expiration Date: Monday, January 1, 2029 NOFO Number: NOT-NS-26-033 Notice of Change to Key Dates for PAR-25-049: NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required) Expiration Date: Thursday, July 9, 2026 NOFO Number: NOT-NS-26-027 pNINDS will extend this funding opportunity for one more receipt date and Council.
/p Notice of Change to Key Dates for RFA-NS-25-017 and RFA-NS-25-018: BRAIN Initiative Technologies for Recording and Modulation in the Nervous System. Expiration Date: Monday, January 1, 2029 NOFO Number: NOT-NS-26-005 Friday, February 13, 2026
According to the current listing, eligibility includes: Universities, Nonprofits, For-profits, State and local governments, Foreign institutions. Confirm the full requirements in the official notice before applying.
Research Grants in Cognitive Neuroscience is funded by National Institute of Neurological Disorders and Stroke (NINDS). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The AIR program is ARPA-H's most ambitious bet yet: fully autonomous robots that perform stroke-saving thrombectomies without a human surgeon. Proposals are due March 18. A strategic guide for applicants.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read articleThe HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read article